

Introducing Our Speakers

**Genomics Education Event
Friday 16 January 2026**

Hyatt Regency Manchester, M15 6PQ



With thanks to our sponsors who will be exhibiting at the event but have had no input into the agenda or content of the day.



Dr Matthew Krebs

Clinical Senior Lecturer in Experimental
Cancer Medicine University of
Manchester

Honorary Consultant in Medical Oncology
The Christie NHS Foundation Trust
Cancer Genomics Clinical Lead North
West Genomics Laboratory Hub

Dr Matt Krebs began specialist training in Medical Oncology at The Christie in 2005 and in 2007 was awarded a Cancer Research UK-AstraZeneca PhD fellowship to research circulating biomarkers and experimental pharmacology. In June 2014 Dr Krebs was appointed to his current position as Clinical Senior Lecturer in Experimental Cancer Medicine at The Christie and University of Manchester. He undertakes early-phase clinical trials of new anti-cancer drugs and researches the use of blood tests to help guide treatment selection and monitor treatment response.

He is a member of the Manchester Experimental Cancer Medicine Steering Board and deputises as the clinical trials theme lead within the Manchester-UCL Lung Cancer Centre of Excellence. Dr Matt Krebs is the clinical lead of GM Cancer Alliance's Genomics Delivery Group and Cancer Medical Lead for the North West Genomics Lab Hub.



Dr Mike Clark

Deputy Clinical Director for Primary Care
North West Genomic Medicine Service
Alliance

“Who am I? I am a GP partner, who like many of you enjoys the benefits of a portfolio career. I have no clinical role in the Genomics Service, and remain a frontline GP, but am passionate in informing the whole Primary Care workforce about the potential benefits and limitations of genetic testing in a Primary Care setting and supporting clinicians and patients in make informed decisions about their healthcare.

I qualified in Medicine and Surgery at The University of Manchester in 1995, became a GP in 2003 and am currently undertaking and MSc in Genomic Medicine. I currently practice in Macclesfield, Cheshire.

Why Genomics? I am particularly interested in how genetic factors influence drug responses/side effects and the optimisation of therapies for patients (Pharmacogenomics) and the use of genetic data to better understand an individual’s risk for common but complex diseases, such as cancer, cardiovascular disease and diabetes (polygenic risk scoring).

My role with NW GMSA is one of representation and supportive integration of primary care in the acceleration of genomics within the NHS. I advocate a considered and cautious approach, that is sympathetic to the needs of Primary Care, in trying to bridge the knowledge gaps as cutting-edge genomics starts to filter down to routine clinical care. The NW GMSA and North Thames GMSA are leading the work in bringing together a set of learning packages for Primary Care as part of the Genomics Education Programme (NHSE). I work with GP, Nursing, Midwifery, Pharmacy and Genomics Educator colleagues from across England ensuring a supportive approach to this expanding field. I also chair the Familial Hypercholesterolaemia mainstreaming Task and Finish Group. I am always happy to speak with any Primary Care colleagues interested in the impacts of Genomics in practice.”

Dr Matthew Evans

Consultant Cellular & Molecular Pathologist
University Hospitals Birmingham NHS
Foundation Trust & Black Country Pathology
Services | Pathology Lead Central and South
Genomic Laboratory Hub | Pathology Lead
Cancer Genomics Improvement Programme



Matthew is a leading expert in molecular pathology across all tumour types, with specialist expertise in thoracic and gastrointestinal pathology. He also works as; the Pathology Lead for Central and South Genomic Laboratory Hub, The Pathology Lead for the NHS England Genomics Unit, and the Pathology Lead for the Cancer Genomics Improvement Programme.

Deborah Porter

Deputy Director
Genomics Service Transformation
Genomics Unit, Specialised Commissioning
NHS England



Deborah has held the appointment of Deputy Director in NHS England since June 2020. Her transformation portfolio includes Operational and Service Management, Informatics and Workforce Development, with particular emphasis on Pharmacy, Nursing and Midwifery. Prior to taking up the role in NHS England, Deborah spent three decades in British Army uniform, with the last 24 years in the Royal Army Medical Corps.



Dr Rehan Naseer

Respiratory and Lung Cancer Physician
Northern Care Alliance NHS Foundation
Trust

Respiratory and lung cancer physician at the Northern care Alliance Foundation Trust. Dr Naseer is the lung cancer lead for the North east Sector of the NCA (Bury, Rochdale and Oldham). My other roles include Greater Manchester (GM) lung cancer MDT reform Lead, GM Self-Referral CXR lead, GM Single queue EBUS sub-group lead, and GM Lung cancer symptomatic early diagnosis lead.



Dr Victoria Foy

Consultant Medical Oncologist
The Christie NHS Foundation Trust

Dr Foy is a consultant medical oncologist at The Christie hospital specialising in the treatment of hepatobiliary and renal cancers. She was awarded a PhD in 2021 after researching circulating biomarkers of cancer during an AstraZeneca Fellowship based at the CRUK Manchester Institute. Dr Foy has been the genomic lead for HPB cancers in the GM region since 2024, establishing new molecular testing pathways for HPB cancers.



Suzanne Frank

Advanced Specialist Breast Cancer
Pharmacist
The Christie NHS Foundation Trust

Suzanne Frank MPharm, Clin Dip, iNMP, Advanced Specialist Breast Cancer Pharmacist, The Christie NHS Foundation Trust.

Suzanne qualified as pharmacist in 2002 and worked as a rotational basic grade pharmacist at The Leeds Teaching Hospitals Trust gaining experience in a number of specialities. In 2006 she specialised as an oncology pharmacist.

In 2008 Suzanne joined The Christie NHS Foundation Trust as an Advanced Specialist Breast Cancer Pharmacist where she qualified as an independent Non-Medical Prescriber. She works in an outpatient clinic setting alongside medical oncology consultants prescribing chemotherapy and supportive care for patients with early and secondary breast cancer. She is in the process of credentialling as a Consultant Pharmacist.

Suzanne is a member of the Greater Manchester Cancer breast pathway board and is passionate about improving patient pathways and access to breast cancer treatment across the region.

Suzanne's research interests include assimilating real world evidence on the efficacy and tolerability of systemic anticancer treatments and analysis of treatment pathways and patient experience to inform future service developments.



Dr Lynne Jamieson

Consultant Dermatopathologist
Northern Care Alliance NHS Foundation
Trust

Dr Lynne Jamieson is a Consultant Dermatopathologist based at Salford Royal Hospital where she reports specialist dermatopathology for NCA tertiary dermatology services, one of the largest in Europe. She has almost 20 years experience in her specialist field and has an interest in melanocytic pathology including the diagnosis of malignant melanoma. In recent years there have been significant advances in the treatment of melanoma including the use of targeted therapies which require molecular genetic assessment. The use of molecular genetics is also becoming integral in the diagnosis of certain melanocytic lesions and can be used to aid not only diagnosis but prognosis.

Dr Jamieson has worked with NICE in the production of the most recent guidelines for the Management of Malignant Melanoma and has also recently worked on a project with GM cancer on reflex testing for BRAF in malignant melanoma.



Dr Rachel Hart

Deputy Clinical Director for Cancer
North West Genomics Medicine Service
Alliance

Dr Rachel Hart MBChB, MRCPCH (2004) MA medical ethics and Law, FRCP is a consultant in clinical genetics and cancer lead at Liverpool centre for genomic medicine. In addition, she is clinical lead for a genomics programme in Alder Hey children's hospital and is on the genomic steering group at Clatterbridge centre for Cancer. Working alongside local and national programmes in the national genomic medicine service, she is a keen advocate of mainstreaming genomic medicine and delivers regular education sessions for non-genetic healthcare professionals. As associate clinical director in the Northwest Genomic Medicine Service she is co-leading on a series of working groups to improve Mainstreaming and Equity of access to genomic testing for patients across the Northwest.

A long-standing member of the British Society for Genomic Medicine ethics and policy group, Rachel also uses her interest in ethics as a member of the local LUFT/LWH Ethics Advisory Group and as Trustee on the board for the institute of Medical Ethics.



Anthony Sutcliffe

Programme Manager
North West Genomics Medicine Service
Alliance

“As a Programme Manager specialising in healthcare transformation across genomics, I lead strategy and implementation for system-level change. At the North West Genomic Medicine Service Alliance, I support delivery of the NHS Long Term Plan by driving genomic service adoption. My work involves innovation, policy, implementation, and clinical transformation, focused on building a future-ready healthcare system. This includes facilitating cutting-edge pilots, such as the ctDNA project, supporting the rollout of ctDNA testing in stage 3/4 non-small cell lung cancer patients within the North West. My focus is delivering scalable, evidence-based models that support future NHS-wide adoption and ensure equitable access to cutting-edge genomic healthcare.”



Dr Liz Jones

Medical Director
North West Genomics Laboratory Hub

Dr Liz Jones is Medical Director for the North West Genomics Laboratory Hub. She is a consultant clinical geneticist in the Manchester Centre for Genomic Medicine specialising in rare diseases with sub-specialty interests in genetic dermatology, ectodermal dysplasia and tuberous sclerosis complex. She is the clinical lead for the Ectodermal Dysplasia Rare Disease Collaborative Network.